B-Cell Depletion Therapy Market Projected to Reach USD 62.6 Billion by 2036

The market's upward trajectory is fueled by the rising prevalence of chronic autoimmune diseases and hematologic malignancies, which necessitate long-term, recurring treatment cycles. Healthcare providers are increasingly integrating targeted biologics into standard clinical guidelines, supported by expanding hospital infusion infrastructure and specialty pharmacy networks. According to Anurag Sharma, a senior healthcare analyst at Future Market Insights, these therapies are transitioning from niche specialist options into foundational elements of long-term disease management, bolstered by improved reimbursement frameworks and growing clinical confidence.

Anti-CD20 monoclonal antibodies currently command a 70% market share, remaining the preferred choice due to their established safety profiles and decades of clinical validation. While next-generation therapies continue to emerge, the sector’s commercial backbone remains rooted in these proven biologics. Geographically, India is expected to lead global growth with a projected 11.2% CAGR, as emerging healthcare systems modernize their infrastructure and improve patient access to advanced immunology care.